Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,991 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, Zhu H, Pan L, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Zhang Y, Li W, Jiang Q. Zhang X, et al. Among authors: tu c. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):e257-e266. doi: 10.1016/j.clml.2024.02.008. Epub 2024 Feb 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38461040
Validation of the imatinib-therapy failure model.
Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, Chen C, Lin H, Li G, Liang R, Liu Z, Wang X, Zhang Y, Han Y, Liu C, Hu J, Lin L, Yang W, Liu Z, Meng L, Tu C, Zheng C, Zhou Z, Bai Y, Qiu H, Chen S, Li F, Guo J, Liu Z, Sun H, Zhou L, Feng R, Sun X, Huang X, Jiang Q. Zhang X, et al. Among authors: tu c. Leukemia. 2023 May;37(5):1166-1169. doi: 10.1038/s41375-023-01875-3. Epub 2023 Mar 27. Leukemia. 2023. PMID: 36973351 No abstract available.
De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China.
Luo J, Du X, Lou J, Wu J, Ma L, Huang J, Wang L, Tu C, Liu Z, Chen L, Tan Y, Luo D, Liang H, Yin C, Cao R, Zhou X, Liu Q, Liu X, Xu N. Luo J, et al. Among authors: tu c. EJHaem. 2022 Sep 19;3(4):1220-1230. doi: 10.1002/jha2.550. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467815 Free PMC article.
[8p11 myeloproliferative syndrome with t(8;22) (p11; q11): a case report].
Huang C, Zou LL, Wang DW, Zhang XY, Li JY, Tu CQ. Huang C, et al. Among authors: tu cq. Zhonghua Xue Ye Xue Za Zhi. 2019 Nov 14;40(11):923. doi: 10.3760/cma.j.issn.0253-2727.2019.11.007. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856441 Free PMC article. Chinese. No abstract available.
[Myeloid sarcoma with acute promyelocytic leukemia:two cases report].
Li J, Tu C, Wang D, Huang C, Zhang X. Li J, et al. Among authors: tu c. Zhonghua Xue Ye Xue Za Zhi. 2015 May;36(5):438-40. doi: 10.3760/cma.j.issn.0253-2727.2015.05.020. Zhonghua Xue Ye Xue Za Zhi. 2015. PMID: 26031537 Free PMC article. Chinese. No abstract available.
2,991 results